Business Context and Reporting Period
This Form 6-K filing by Can-Fite Biopharma Ltd. covers the month of April 2025, specifically dated April 15, 2025. The filing announces a registered direct offering of equity securities to raise capital.
Key Financial Metrics and Transaction Details
- Offering Size: 750,000,000 ordinary shares represented by 2,500,000 American Depositary Shares (ADSs).
- Offering Price: $1.20 per ADS.
- Gross Proceeds: Approximately $3.0 million.
- Placement Agent Fees: 7.0% cash placement fee, 1.0% management fee, and a non-accountable expense allowance of $25,000 (up to $50,000 for legal/out-of-pocket expenses).
- Warrants Issued: 52,500,000 ordinary shares (175,000 ADSs) representing 7.0% of the offering, with an exercise price of $1.50 per ADS and a term expiring April 14, 2030.
- Expected Closing Date: On or about April 15, 2025.
The filing text does not provide clear values for revenue, profit, cash flow, margins, or existing debt levels as this is a transaction announcement rather than a periodic financial report.
Material Changes and Restrictions
The Company entered into a Securities Purchase Agreement on April 14, 2025. Key contractual restrictions include:
- Variable Rate Transaction Restriction: For one year following the closing date, the Company cannot effect or agree to a "variable rate transaction."
- Standstill Restrictions: The Company agreed to customary standstill restrictions for 60 days following the closing date, subject to exceptions.
Outlook, Risks, and Contingencies
The closing of the offering is subject to customary conditions and contingencies. The filing includes a warning concerning forward-looking statements, noting that the expected closing date is not guaranteed. If conditions are not satisfied, the offering may not close. The Company undertakes no obligation to update these statements.
Investor Verification Checklist
- Confirm the actual closing of the offering and the final net proceeds after deducting all fees and expenses.
- Verify the dilution impact of the 750,000,000 new ordinary shares and the 52,500,000 warrant shares on existing shareholders.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and conditions precedent.
- Monitor the Company's cash runway post-offering to assess operational sustainability.